Month: December 2022

Posted on

2022: The MILESTONE YEAR

Jetex Annual Review

Dubai, United Arab Emirates, Dec. 29, 2022 (GLOBE NEWSWIRE) — The business aviation industry is currently going through the biggest transition in history, accelerated by the digitalisation, accessibility, and the exceptional travel conveniences that it offers against the backdrop of a gradual recovery from the health crisis. In many ways, it reflects the fourth industrial revolution, which is more significant, and its ramifications more profound, than in any prior period of human history.

With the private jet traffic setting new records in 2022, experts predict up to 8,500 new business jet deliveries until 2031, which amounts to an estimated total value of US$ 274 billion. At the same time, sustainability is at the top of the agenda to ensure that the industry develops in line with the decarbonisation goals set by IATA.

The record results could not have been achieved without the efficiency and exceptional ability of the business aviation industry to adapt and to remain connected to its customers, continuing to inspire their desire to travel and discover.

For the first time, Jetex invites you to discover the latest trends in private aviation, and what will shape the global industry in the future in its interactive annual review.

Discover

About Jetex:

An award-winning global leader in executive aviation, Jetex is recognized for delivering flexible, best-in-class trip support solutions to customers worldwide. Jetex provides exceptional private terminals (FBOs), aircraft fueling, ground handling and global trip planning. The company caters to both owners and operators of business jets for corporate, commercial and personal air travel. To find out more about Jetex, visit www.jetex.com and follow us on Instagram, Twitter, Facebook, and LinkedIn.

 

Attachment

Oleg Kafarov - Director of Portfolio Development & Corporate Communications
Jetex
+971 4 212 4900
teamorange@jetex.com

GlobeNewswire Distribution ID 8721507

Posted on

Abel Noser Finishes Year with an Impressive List of Achievements

Highlights Include New Product Launches, Numerous Industry Partnerships, and a Ramping Up of Trade Surveillance Services

New York, NY, Dec. 29, 2022 (GLOBE NEWSWIRE) — Abel Noser Holdings, the market leader in institutional trade analytics and agency-only trading solutions, has many notable achievements to look back on this year as 2022 comes to a close.

For instance, the company’s analytics arm, Abel Noser Solutions, began offering a first-of-its-kind global options TCA product that covers all options strategies from covered calls to complex spread strategies.  The offering enables clients to quantify the transaction costs of options hedging, income and more speculative strategies while evaluating broker performance metrics and execution quality.  There were also many enhancements to the firm’s fixed income TCA product suite.

Subsidiary Zeno AN Solutions launched an ESG-agnostic consensus ratings product for asset owners that provides portfolio-level analysis to help assess, measure and monitor the degree to which manager practices are consistent with client ESG policies. On the broker-dealer side, Abel Noser LLC’s revolutionary START platform, a customizable execution algorithmic solution integrated with industry-leading analytics, was rolled-out as a way for fund managers to proactively meet diversity and inclusion goals through a network of participating MWBE brokers while also mitigating best execution risk in an increasingly challenging trading environment.

Sell-side regulatory services had a busy year including partnering with Capital Market Solutions to offer clients comprehensive FINRA CAT and CAIS solutions before key 2022 deadlines. Additionally, the group developed a set of new regulatory tools to help brokers identify improper or illegal trading activity while also evidencing best execution.  Firm clients continue to call for cost-effective auditing and reporting tools, as well as regulatory services to mitigate their ongoing risk of potential fines or damage to their reputations.

2022 was also a busy year for Abel Noser channel partnerships including strategic liaisons with major industry players like JP Morgan’s Neovest.  Partnerships with more niche players included working with the Hackett Group for MWBE brokerage programs, and OWL ESG for consensus ESG data that powers the new fund holdings analysis product.

“As for the coming year, Abel Noser expects best execution requirements for brokers and managers to continue to be updated and quantified including calls for more fixed income transparency, pending updates to SEC Rule 605 and various FINRA directives,” remarked Peter Weiler, Co-CEO of Abel Noser Holdings. “We also expect a continued ramping up of electronic and algorithmic trading, plus greater emphasis on trading clarity and oversight from all sectors.”

“We’re proud of the many successes our top-notch team has accomplished this past year,” added Steve Glass, Co-CEO of Abel Noser Holdings. “We again look forward to applying the firm’s resources and leading position as the overall market matures and becomes more data-driven.”

About Abel Noser Holdings
Abel Noser has long been respected as a leader in the campaign to lower the costs associated with trading. Abel Noser Solutions, the company’s analytics subsidiary, is the industry-leading provider of transaction cost analysis with hundreds of global clients subscribing to its multi-asset TCA and compliance products through a network of resellers, distribution partners and strategic alliances. Abel Noser LLC, the company’s registered broker-dealer and a member of FINRA, SIPC and MSRB, provides a wide range of agency-only trading, transition management, and analytics services to institutional asset owners, investment managers and brokers. Learn more at www.abelnoser.com.

Attachment

Jerry Boak
Abel Noser
646-432-4000
jboak@abelnoser.com

GlobeNewswire Distribution ID 8721121

Posted on

Scientists Study Link Between Winter Storms and Global Warming

The world is getting warmer, winters included. The United States, however, has experienced severe winter storms in recent years, and experts are taking a closer look at the link between these extreme cold events and climate change.
While the link between global warming and heat waves is very direct, the behavior of winter storms is governed by complex atmospheric dynamics that are more difficult to study.
Even so, “there are certain aspects of winter storms … where the climate change linkages are fairly strong and robust,” Michael Mann, a climatologist at the University of Pennsylvania, told AFP.
For example, the warming of bodies of water — lakes or oceans — influences the amount of snowfall.
In the United States, a mechanism called “lake-effect snow” occurs around the Great Lakes region on the Canadian border. The city of Buffalo, which sits on the shores of one of the Great Lakes, was hit hard by a lethal snowstorm over Christmas weekend.
The collision between cold air from the north with the warmer water of these lakes causes convection, which leads to snowfall.
“The warmer those lake temperatures, the more moisture (is) in the air, and the greater potential for lake-effect snows,” Michael Mann wrote in a 2018 paper.
“Not surprisingly, we see a long-term increase in lake effect snowfalls as temperatures have warmed during the last century.”
Polar vortex
There is, however, no consensus on other mechanisms, such as the effect of climate change on the polar vortex and jet stream air currents.
The polar vortex is an air mass above the North Pole, located high in the stratosphere. Humans dwell in the troposphere, and the stratosphere is located just above it.
It is surrounded by a band of rotating air, which acts as a barrier between the cold air in the north and the warmer air in the south. As the polar vortex weakens, this band of air begins to undulate and take on a more oval shape, bringing more cold air southward.
According to a 2021 study, this type of disturbance is occurring more often and is reflected during the following two weeks, lower in the atmosphere, where the jet stream is located.
This air current, which blows from west to east, again following the border between cold and warm air, then meanders in such a way that it allows cold air from the north to intrude at lower latitudes, particularly over the eastern United States.
“Everybody agrees that when the polar vortex becomes perturbed or disrupted, there is an increase in the probability of severe winter weather,” Judah Cohen, lead author of the study and climatologist for Atmospheric and Environmental Research (AER), told AFP.
And this “stretched” polar vortex is exactly what was observed just before the storm that hit the United States this December, he pointed out.
The same phenomenon was seen in February 2021, when a bitter cold snap hit Texas, causing massive power outages.
‘Active debate’
But the heart of the debate lies elsewhere: What is causing these increased disturbances in the polar vortex?
According to Cohen, they are linked to changes in the Arctic, accelerated by climate change. On the one hand, the rapid melting of sea ice, and on the other, an increase in snow cover in Siberia.
“This is a topic that I have been studying for over 15 years, and I am more confident today in the link than I have ever been in the past,” he told AFP.
This last point, however, remains “an active debate within the scientific community,” Mann said.
“Climate models are not yet capturing all of the underlying physics that may be relevant to how climate change is impacting the behavior of the jet stream.”
Future studies will still be needed in the coming years to unravel the mystery of these complex chain reactions.

Source: Voice of America

Posted on

US Considers Airline Wastewater Testing as COVID Surges in China

As COVID-19 infections surge in China, the U.S. Centers for Disease Control and Prevention is considering sampling wastewater taken from international aircraft to track any emerging new variants, the agency told Reuters.
Such a policy would offer a better solution to tracking the virus and slowing its entry into the United States than new travel restrictions announced this week by the U.S. and other countries, which require mandatory negative COVID tests for travelers from China, three infectious disease experts told Reuters.
Travel restrictions, such as mandatory testing, have so far failed to significantly curb the spread of COVID, said Dr. Michael Osterholm, an infectious disease expert at the University of Minnesota.
“They seem to be essential from a political standpoint. I think each government feels like they will be accused of not doing enough to protect their citizens if they don’t do these,” he said.
The United States this week also expanded its voluntary genomic sequencing program at airports, adding Seattle and Los Angeles to the program. That brings the total number of airports gathering information from positive tests to seven.
But experts said that may not provide a meaningful sample size.
A better solution would be testing wastewater from airlines, which would offer a clearer picture of how the virus is mutating, given China’s lack of data transparency, said Dr. Eric Topol, a genomics expert and director of the Scripps Research Translational Institute in La Jolla, California.
Getting wastewater off planes from China “would be a very good tactic,” Topol said, adding that it’s important that the United States upgrade its surveillance tactics “because of China being so unwilling to share its genomic data.”
China has said criticism of its COVID statistics is groundless and downplayed the risk of new variants, saying it expects mutations to be more infectious but less severe. Still, doubts over official Chinese data have prompted many places, including the United States, Italy and Japan, to impose new testing rules on Chinese visitors as Beijing lifted travel controls.
Airplane wastewater analysis is among several options the CDC is considering to help slow the introduction of new variants into the United States from other countries, CDC spokesperson Kristen Nordlund said in an email.
The agency is grappling with a lack of transparency about COVID in China after the country of 1.4 billion people abruptly lifted strict COVID lockdowns and testing policies, unleashing the virus into an under-vaccinated and previously unexposed population.
“Previous COVID-19 wastewater surveillance has shown to be a valuable tool and airplane wastewater surveillance could potentially be an option,” she wrote.
French researchers reported in July that airplane wastewater tests showed requiring negative COVID tests before international flights does not protect countries from the spread of new variants. They found the omicron variant in wastewater from two commercial airplanes that flew from Ethiopia to France in December 2021 even though passengers had been required to take COVID tests before boarding.
California researchers reported in July that sampling of community wastewater in San Diego detected the presence of the alpha, delta, epsilon and omicron variants up to 14 days before they started showing up on nasal swabs.
Osterholm and others said mandatory testing before travel to the United States is unlikely to keep new variants out of the country.
“Border closures or border testing really makes very little difference. Maybe it slows it down by a few days,” he said, because the virus is likely to spread worldwide, and could infect people in Europe or elsewhere who may then bring it to the United States.

Source: Voice of America

Posted on

Gov’t asked to ensure GDP grows by 4.5%

At the ongoing 4th Ordinary Session of the National Assembly, people representatives have urged the government to ensure the country’s economy grows by at least 4.5% and per capita incomes and GNI are increased.
Members of the National Assembly have noted that it is obvious that several sectors and provinces have potentials and are likely to collect enough revenues that can ensure they have budget sufficiency and exceed revenue collection plans.
Giving an interview to the media on Wednesday, Vice President of the National Assembly Sommad Pholsena said that the government has been urged to make efforts in mobilizing financial resources through promoting domestic and foreign investment, ODAs, stock market development, and making use of existing funds to achieve targets of its National Socio-economic Development Plan.
It has been asked to attach greater attention to promoting domestic and foreign investment in special and specific economic zones by taking into account lessons learned in neighbouring countries and other friendly countries.
The National Assembly has urged strict management of state investment projects, and proper consideration of measures that can help better tap domestic potentials including the Laos-China railway, dry ports, special economic zones and other economic sectors to promote the country’s connectivity.
People’s representatives have called on the government to promote domestic production to reduce imports, help local businesses access carbon funds, accelerate devising land use strategic plans of each sector and province, and pay adequate attention to basic infrastructure development in the education sector.
They have called on the government to reallocate civil servant quotas, devise an incentive policy for volunteer teachers and volunteer health workers, especially those working in remote areas, and provide educational equipment and textbooks to all schools across the country, address school dropout problems and encourage secondary school graduates to pursue education at tertiary, vocational and university levels as well as address malnutrition problems among children, and improve the health insurance system.
NA has also urged the government to continue to reform state enterprises, attach attention to evaluating and implementing priority projects of rural development and poverty reduction in target districts, promote rule of law and address social shortcomings in a strict, transparent and professional fashion, take decisive actions against the budget units that violate planning and investment regulations, and attach importance to the implementation of the three-build directive along with the patriotism and development movement and urge local administrations to be more active in developing their localities.
The National Assembly has also asked the government to pay attention to implementing the national agenda on addressing economic and financial difficulties as a priority of the National Socio-economic Development Plan and make sure a significant progress is made to ensure the country will not fall into an economic recession, and come up with measures that can mobilize funding in a certain, stable, sustainable manner especially from domestic partners to cut public debts to less than 64.5% of GDP and foreign debts to less than 55.4% of GDP.
NA has also noted that it is necessary for the government to strengthen revenue collection in the tourism sector and make the best use of Laos-China railway, establish local production and goods zones in each province and ensure their processing is diverse and low interest loans are accessible to reduce costs of local producers and increase the competitiveness of local products against imported ones.
The government has been asked to attach attention to improving land tax collection by using an integrated banking system, increasing effectiveness of state spending management, and evaluating the provision of loans to small and medium enterprises, young entrepreuners and producers including the 300-billion-kip package for SMEs and the Bank of the Lao PDR’s 1.8 trillion kip loan to relieve Covid-19 impacts.

Source: Lao News Agency

Posted on

Junshi Biosciences Announces NEJM Publication of Results of Phase 3 Study of VV116 Versus PAXLOVID for Adults at High Risk for Progression to Severe COVID-19

SHANGHAI, China, Dec. 29, 2022 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announces the online publication in New England Journal (NEJM) of the Phase 3 trial (NCT05341609) comparing the efficacy and safety of VV116 (JT001) and nirmatrelvir/ritonavir (“PAXLOVID”) in the treatment of symptomatic patients with mild to moderate COVID-19 who are at high risk for progression to severe COVID-19 including death. It is the first time that NEJM published the clinical trial results of China-developed anti-SARS-CoV-2 drug.

The study, led by Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, is the first “head-to-head” phase III clinical study of small molecule oral anti-SARS-CoV drug in Chinese COVID-19 patients during the Omicron outbreak. The results indicated that the primary endpoint of the study realized the designed noninferiority endpoint, and VV116 group had a shorter time to sustained clinical recovery with less safety concerns as compared with PAXLOVID.

The Article was co-authored by Professor Ren ZHAO of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Professor Yuan GAO of Renji Hospital, Shanghai Jiao Tong University School of Medicine, Professor Guang NING, Professor Yiping XU and Professor Qing XIE of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine as co-corresponding authors, Zhujun CAO and Weiyi GAO of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Hong BAO of Pudong Hospital, Fudan University, Haiyan FENG of Shanghai Public Health Clinical Center and Shuya MEI of Renji Hospital, Shanghai Jiao Tong University School of Medicine as co-first authors.

“Thanks to the support of the patients and study team, we have achieved great success in this clinical study and were recognized by the prestigious New England Journal of Medicine,” said Professor Ren ZHAO. “Our study not only provided valuable information and experience for the development and clinical application of two major anti-SARS-CoV-2 small molecule drug routes, the RdRp inhibitor and the 3CL protease inhibitor, but also showed that our self-developed anti-SARS-CoV-2 oral drugs in China have similar efficacy and safety to PAXLOVID. We hope that our study results can assist in our nation’s efforts to combat the epidemic.”

“Presently, the treatment and prevention of COVID-19 is still full of challenges, particularly in the treatment of patients who are at high risk for progression to severe COVID-19,” said Jianjun ZOU, Global Research and Development President at Junshi Biosciences. “The current treatment needs to be made more widely applicable and accessible to a larger population. The publication of this study in the NEJM demonstrates that the international academic community has recognized the clinical development of drugs led by Chinese investigators and pharmaceutical companies in terms of trial design, quality, and results. We are continuing to invest in the clinical development of VV116 for use in other populations, with the goal of providing better and safer treatment options for COVID-19 patients in China and around the world with this exciting new therapy!”

At present, the COVID-19 pandemic continues to spread rapidly worldwide, and the transmission and escape ability of the virus continues to increase with variation. Oral antiviral drugs are considered to be one of the essential response against the pandemic because of their advantages of convenient administration, high resistance barrier, and less transportation and storage restrictions, which help to alleviate the medical burden. However, there are still a number of factors that lead to limited use of the drugs (such as the interaction between drug and drug, accessibility, etc.), so more effective and safe therapeutic drugs need to be developed.

VV116 is an oral nucleoside antiviral drug independently developed in China that inhibits the replication of SARS-CoV-2. Preclinical studies have shown that VV116 had significant antiviral effects in both original strain and known mutant strains, and exhibited satisfactory safety, tolerability, and pharmacokinetic properties in phase I clinical studies1. A preliminary small-scale study confirmed that patients, who were treated with VV116 within 5 days since they were tested positive after the first SARS-CoV-2 detection, had a shorter time to nucleic acid reversion compared to conventional therapy2.

This publication is related to a multicenter, single-blind (observers remain blinded), randomized, controlled Phase III clinical trial (NCT05341609) conducted jointly at seven COVID-19 designated hospitals in Shanghai from April 4 to May 2, 20223, which included a total of 822 adult patients with mild to moderate COVID-19 diagnosed at high risk of progression and assigned to the VV116 group and PAXLOVID group on a proportion of 1:1. Finally, a total of 771 patients (Full Analysis Set, FAS) were treated with VV116 (n = 384) or PAXLOVID (n = 387).

Among them, the median age of FAS patients was 53 (range: 18-94), 50.2% of them were female, 92.1% of them had mild COVID-19, 75.7% of them were fully vaccinated or boosted, and 77.3% of them received VV116 or PAXLOVID therapy within 5 days after symptom onset. The most common high-risk factors in patients were: age ≥ 60 years (37.7%), cardiovascular disease including hypertension (35.1%), obesity or overweight BMI ≥ 25 (32.9%), current smoking (12.5%), and diabetes (10.1%).

The primary end point of the study was the time from randomization to sustained clinical recovery, with a lower boundary of the two-sided 95% confidence interval (CI) for the hazard ratio (HR) > 0.8 defined as noninferiority. Secondary efficacy end points included the proportion of patients who progressed to severe or critical COVID-19 or death from any cause by Day 28, the change in COVID-19 related symptom score and the score on the WHO Clinical Progression Scale, time to sustained resolution of all target symptoms, and to a first negative SARS-CoV-2 test. Safety endpoints included adverse events (AEs) and serious adverse events (SAEs).

According to the final analysis (as of August 18, 2022), VV116 and PAXLOVID achieved noninferiority in the “time to sustained clinical recovery” in the FAS population (HR = 1.17, 95% CI: 1.02~1.36), and the median time to sustained clinical recovery was shorter in the VV116 group than that in the PAXLOVID group (4 days vs. 5 days).

For VV116 group and PAXLOVID group, they showed similar results in respect of “time to sustained resolution of all target symptoms” and “time to a first negative SARS-CoV-2 test”, with a median time of 7 days. At each preset time point (Days 5, 7, 10, 14, and 28), the proportion of patients with clinical recovery was larger in the VV116 group than that in the PAXLOVID group. No patients in either group hase progression to severe/critical COVID-19 or had died.

In addition, about 3/4 of the patients in this study had vaccinated against SARS-CoV-2, and such patients have been excluded from most trials, and subgroup analysis showed that there was no statistically significant difference in the treatment results between VV116 and PAXLOVID in the vaccinated or unvaccinated population.

VV116 showed fewer safety concern than PAXLOVID. The incidence of AEs in VV116 group was lower than that in the PAXLOVID group (all-grade AEs: 67.4% vs. 77.3%, Grade 3 or 4 AE: 2.6% vs. 5.7%).

It should be noted that PAXLOVID has multiple drug-drug interactions, while VV116 does not inhibit or induce major drug-metabolism enzymes, or inhibit major drug transporters, and is therefore less likely to interact with the drugs for combination therapy.

About VV116 (JT001)
VV116 is an oral nucleoside analog drug that can inhibit the replication of SARS-CoV-2. During preclinical pharmacodynamic studies, VV116 exerted an antiviral effect on the original strain of the novel coronavirus and its known variants in vitro; in the mice model, a low dose of VV116 reduced the virus titers below the detection limit, significantly lowered the chances of lung injury and displayed a strong antiviral effect. Preclinical pharmacokinetics and other research results also show that VV116 has high oral bioavailability. Following oral administration and absorption, VV116 is rapidly metabolized into parent nucleoside and widely distributed throughout the body.

VV116 was jointly developed by the Shanghai Institute of Materia Medica, Chinese Academy of Sciences; the Wuhan Institute of Virology, Chinese Academy of Sciences; Xinjiang Technical Institute of Physics and Chemistry, Chinese Academy of Sciences; Central Asian Center of Drug Discovery and Development Chinese Academy of Sciences / China-Uzbekistan Medicine Technical Park (the Joint Laboratory of the Ministry of Science and Technology under the “The Belt and Road Initiative”); Lingang Laboratory; Vigonvita Life Sciences Co., Ltd. (“Vigonvita”); and Junshi Biosciences. Junshi Biosciences and Vigonvita are responsible for the clinical development and industrialization of VV116 worldwide. The areas of cooperation is global aside from five Central Asian countries, Russia, North Africa and the Middle East.

Junshi Biosciences and Vigonvita have completed three Phase I studies with healthy Chinese subjects, and one Phase III study in the patients with mild-to moderate COVID-19 at high risk to progression to severe COVID-19 in China (NCT05341609). Research results have been published in Acta Pharmacologica Sinica, and NEJM respectively.

In 2021, VV116 was approved in Uzbekistan for the treatment of patients diagnosed with moderate to severe COVID-19.

About Junshi Biosciences
Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. The company has established a diversified R&D pipeline comprising over 50 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA monoclonal antibody for the treatment of various cancers was the first in the world to be approved for clinical trials by the FDA and NMPA and has since entered Phase Ib/II trials in both China and the US. Its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA.

In the face of the pandemic, Junshi Biosciences’ response was strong and immediate, joining forces with Chinese and international scientific research institutions and enterprises to develop an arsenal of drug candidates to combat COVID-19, taking the initiative to shoulder the social responsibility of Chinese pharmaceutical companies by prioritizing and accelerating COVID-19 R&D. Among the many drug candidates is JS016 (etesevimab), China’s first neutralizing fully human monoclonal antibody against SARS-CoV-2 and the result of the combined efforts of Junshi Biosciences, the Institute of Microbiology of the Chinese Academy of Science and Lilly. JS016 administered with bamlanivimab has been granted Emergency Use Authorizations (EUA) in over 15 countries and regions worldwide. As of December 3 2021, over 700,000 patients have been treated with bamlanivimab or bamlanivimab and etesevimab, potentially preventing more than 35,000 hospitalizations and at least 14,000 deaths. Meanwhile, VV116, a new oral nucleoside analog anti-SARS-CoV-2 drug designed to hinder virus replication, is in global Phase III clinical trials. The JS016 and VV116 programs are a part of the company’s continuous innovation for disease control and prevention of the global pandemic.

Junshi Biosciences has more than 3,100 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing, Guangzhou, etc). For more information, please visit: http://junshipharma.com.

Junshi Biosciences Contact Information
IR Team:
Junshi Biosciences
info@junshipharma.com
+ 86 021-6105 8800

PR Team:
Junshi Biosciences
Zhi Li
zhi_li@junshipharma.com
+ 86 021-6105 8800

1 Qian, Hj., et al. Acta Pharmacol Sin (2022).
2 Shen Y, et al. Emerg Microbes Infect 2022;11:1518-23.
3 The seven hospitals participating in the study were: Ruijin Hospital, Shanghai Jiao Tong University School of Medicine; Renji Hospital, Shanghai Jiao Tong University School of Medicine; Pudong Hospital, Fudan University; Shanghai Public Health Clinical Centre; Shuguang Hospital, Shanghai University of Traditional Chinese Medicine; Huashan Hospital, Fudan University; and Tong Ren Hospital, Shanghai Jiao Tong University School of Medicine.

GlobeNewswire Distribution ID 8721274